COMPARATIVE EFFECTIVENESS OF ALTERNATIVE EMERGING MEDICATIONS ON SYMPTOM BURDEN AND CLINICAL DISEASE ACTIVITY IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE (COMPARE)
PI(s): Michael Kappleman (University North Carolina Chapel Hill)
Purpose: This study will compare the safety and effectiveness of treating inflammatory bowel disease (IBD) in children with medications approved for use to treat adults with IBD.
Study Design: Multi-CRN Observational study requiring recruitment
PCORnet® Partners:
- GPC
- INSIGHT
- OneFlorida+
- PEDSnet
- REACHnet
- STAR
PaTH Partners:
- JHU - Harold Lehmann, Kevin Cesa
- U-M - Jeremy Adler
- PSU - Marc Schaefer
- PITT/UPMC - Whitney Sunseri
Sponsor: PCORI®
The COMPARE study is a PCORnet® Study conducted using PCORnet®, the National Patient Centered Clinical Research Network, an initiative funded by the Patient-Centered Outcomes Research Institute (PCORI). More information about PCORnet® can be found here.
The COMPARE study was funded by PCORI through PCORI Award BPS-2024C1-38861.
The statements presented on this website are solely the responsibility of the author(s) and do not necessarily represent the views of other organizations participating in, collaborating with, or funding PCORnet or of PCORI.
Coordinating Center: University of North Carolina Chapel Hill
